After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.

Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.

Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.

China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.